Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Bausch and Lomb
Bausch and Lomb
X
LinkedIn
Trending Articles
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Fasenra for EGPA: addressing unmet needs
Benralizumab could offer patients with EGPA more treatment options, while reducing dependency on oral corticosteroids
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
Bristol Myers Squibb and Cellares partner to expand CAR-T manufacturing capabilities
Cellares will optimise and automate select Bristol Myers Squibb CAR-T cell therapies onto its high-throughput manufacturing program, the Cell Shuttle
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Finance
Valeant Pharmaceuticals to acquire Synergetics USA
Acquisition will further enhance Bausch + Lomb's presence around the world in the rapidly evolving field of vitreoretinal surgery
Finance
Valeant to purchase Bausch + Lomb for US$8.7bn
Will establish Valeant as a global leader in eye health and dermatology
Finance
Bausch + Lomb to purchase ISTA Pharmaceuticals for US$500m
Adds anti-inflammatory, allergy and glaucoma products to portfolio
Finance
Bausch + Lomb launches pharmaceuticals business in India
Partnership with Micro Labs will provide high quality manufacturing capabilities
Finance
Bausch + Lomb names global president, pharmaceuticals
Daniel Wechsler joins from Merck & Co
Research & Development
Bausch + Lomb wins rights to NCX 116
Worldwide rights for the NCX 116 compound have been granted to Bausch + Lomb for the treatment of glaucoma and ocular hypertension.
Media
Bausch & Lomb sets up global pharma hq in New Jersey
<p>Bausch & Lomb is to open its global pharmaceutical headquarters in Madison, US on Monday, 20 July.</p>
Subscribe now